F9813

Fludarabine phosphate

• Synonim(y): 2-Fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amine
• Wzór empiryczny (zapis Hilla): C₁₀H₁₃FN₅O₇P
• Numer CAS: 75607-67-9
• Masa cząsteczkowa: 365.21
• MDL number: MFCD00866418
• UNSPSC Code: 51102829
• NACRES: NA.85

Właściwości

• form: powder
• Quality Segment: 200
• color: white
• solubility: DMSO: soluble
• antibiotic activity spectrum: neoplastics
• mode of action: DNA synthesis | interferes
• storage temp.: −20°C
• SMILES string: Fc1nc2[n](cnc2c(n1)[N+H3])C3OC(C(C3O)O)CO[P](=O)([O-])O
• InChI: 1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)
• InChI key: GIUYCYHIANZCFB-UHFFFAOYSA-N

Opis

General description

Fludarabine is a purine analog included in the category of DNA-damaging drugs with well-known efficacy in B-cell chronic lymphocytic leukemia (B-CLL).[1]

Application

• Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, Corynebacterium matruchotii, via Bioactivity-HiTES.: This study explores the interactions of clinical drugs like Fludarabine phosphate with Corynebacterium matruchotii, highlighting potential impacts on oral microbiota and implications for drug efficacy and safety (Lee DY et al., 2024).


• Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours.: Investigates the efficacy of a combination of Fludarabine phosphate with other chemotherapeutics delivered via nanocarriers, aiming to enhance treatment outcomes for pancreatic cancer by improving drug delivery to the tumor site (Rudolph D et al., 2024).


• Macrophage neogenin deficiency exacerbates myocardial remodeling and inflammation after acute myocardial infarction through JAK1-STAT1 signaling.: This research demonstrates the role of Fludarabine phosphate in modulating inflammation and cardiac repair post-myocardial infarction, offering insights into its potential therapeutic benefits beyond oncology (Zhang J et al., 2023).


• SLC25A51 promotes tumor growth through sustaining mitochondria acetylation homeostasis and proline biogenesis.: Discusses the cellular mechanisms by which Fludarabine phosphate may influence metabolic pathways in cancer cells, highlighting its potential to disrupt tumor metabolism and promote cancer cell death (Li Y et al., 2023).


• CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.: Reviews the use of Fludarabine phosphate in preconditioning regimens for CAR T-cell therapy, emphasizing its role in enhancing the efficacy of immunotherapy in treating autoimmune disorders (Pecher AC et al., 2023).

Biochem/physiol Actions

Fludarabine represses DNA replication and suppresses the nucleotide metabolism by inhibiting the enzyme ribonucleotide reductase.[2]

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS08
• signalword: Warning
• hcodes: H341,H361d
• pcodes: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Muta. 2 - Repr. 2
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable